MaaT Pharma decided today to end the Phase Ib CIMON study for MaaT03, the company’s second drug candidate and first oral formulation in Phase 1b clinical trial, following positive interim engraftment data of the drug.
Sorrento Therapeutics announced its COVID-19 treatment, Covishield, shows major progress in neutralizing Omicron and Omicron (+R346K) variants of SARS-COV-2.
The SPAC announced it is merging with medical technology company ProKidney LP, in a deal that values the combined equity of the companies at $2.64 billion.
The new building is expected to be ready for occupation in the fourth quarter of 2022 and will feature purpose-built laboratory infrastructure, full-service onsite amenities and multi-functional outdoor spaces.
Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.
One hundred percent of test serum samples showed neutralization of the delta variant, and more than ninety percent of serum samples showed neutralization of the Omicron variant.
BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.
California-based AN2 Therapeutics secured $80 million in a Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.
Ambagon Therapeutics closes its first financing round with $85 million. The Series A funds will help advance the company’s drug discovery platform and molecular glue pipeline.
A billion-dollar real estate project is coming to Morrisville, NC, as developers hope to capitalize on the growing biotechnology industry in the state’s Research Triangle.
DNA Script announced it secured a $200 million Series C financing, bringing the total amount raised by the biotech company to $315 million since its founding in 2014.
